Dr Reddys Laboratories RDY
NYSE RDY
$11.85 -0.03 (-0.29%)
As of: Sep 9, 2026 · 3:06 PM EDT

Dr Reddys Laboratories (RDY) Non-Current Assets (2009 - 2026)

Dr Reddys Laboratories (RDY) posted Non-Current Assets of $2.9 billion for Q2 2026, down 3.93% on a QoQ basis from $3.0 billion in Q1 2026, and little changed year-over-year from $2.9 billion in Q2 2025.

Analysis

Dr Reddys Laboratories (RDY) Non-Current Assets (2009 - 2026) Analysis & Trends

Dr Reddys Laboratories has reported Non-Current Assets for 18 years, with the latest figure at $2.9 billion in Q2 2026.

  • On a quarterly basis, Non-Current Assets changed 0.07% year-over-year to $2.9 billion in Q2 2026; TTM through Jun 2026 was $2.9 billion, a 0.07% change from a year earlier, with the FY2026 full-year figure at $3.0 billion, up 3.94% from the prior year.
  • Non-Current Assets was $2.9 billion for Q2 2026 at Dr Reddys Laboratories, down from $3.0 billion in the prior quarter.
  • The five-year high for Non-Current Assets was $3.0 billion in Q1 2026, with the low at $1.4 billion in Q4 2022.
  • Average Non-Current Assets over 5 years is $2.1 billion, with a median of $1.7 billion recorded in 2024.
  • The sharpest annual moves came in 2022 and 2024: Non-Current Assets slipped 9.42% in 2022, then soared 67.37% in 2024.
  • Over 5 years, Non-Current Assets stood at $1.4 billion in 2022, then gained by 15.4% to $1.6 billion in 2023, then jumped by 67.37% to $2.7 billion in 2024, then gained by 10.33% to $3.0 billion in 2025, then dropped by 2.17% to $2.9 billion in 2026.
  • The last three Non-Current Assets figures came in at $2.9 billion (Q2 2026), $3.0 billion (Q1 2026), and $3.0 billion (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Teva Pharmaceutical Industries 42.53 Bn 38.88 Bn 2.15 Bn 26.10 Bn
2 Viatris 19.14 Bn 18.25 Bn 1.46 Bn 24.99 Bn
3 Dr Reddys Laboratories 9.86 Bn 9.69 Bn 396.53 Mn 2.92 Bn
4 Amneal Pharmaceuticals 5.45 Bn 5.33 Bn 334.51 Mn 1.83 Bn
5 Bausch Health Companies 2.33 Bn 492.63 Mn 2.10 Bn 18.27 Bn
6 Alvotech 1.51 Bn 1.36 Bn 2.56 Mn 1.04 Bn
7 Ani Pharmaceuticals 1.48 Bn 1.12 Bn 165.89 Mn 668.68 Mn
8 Amphastar Pharmaceuticals 992.90 Mn 702.78 Mn 93.47 Mn 1.11 Bn
9 Fennec Pharmaceuticals 400.20 Mn 358.95 Mn 17.15 Mn 3.25 Mn
10 RedHill Biopharma 178.79 Mn 178.79 Mn - 18.82 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.92 Bn
Mar 31, 2026 3.03 Bn
Dec 31, 2025 2.98 Bn
Sep 30, 2025 3.01 Bn
Jun 30, 2025 2.92 Bn
Mar 31, 2025 2.80 Bn
Dec 31, 2024 2.70 Bn
Sep 30, 2024 2.60 Bn
Jun 30, 2024 1.75 Bn
Mar 31, 2024 1.68 Bn
Dec 31, 2023 1.61 Bn
Sep 30, 2023 1.56 Bn
Jun 30, 2023 1.52 Bn
Mar 31, 2023 1.43 Bn
Dec 31, 2022 1.40 Bn
Sep 30, 2022 1.45 Bn
Jun 30, 2022 1.51 Bn
Mar 31, 2022 1.48 Bn
Dec 31, 2021 1.54 Bn
Sep 30, 2021 1.56 Bn